Efficacy of Serratus Posterior Intercostal Plane Block for Analgesia and Inflammatory Marker in Breast Surgery

NCT06502067 | Not Yet Recruiting

• 1 other identifier: MD94/2024
• Study Type: interventional
• Target: 80
• Locations: 0 countries
• Sites: N/A

Brief Summary

To study the efficiacy of serratus posterior superior block in controlling perioperative breast cancer surgery pain and its effect on inflamatory markers.

Conditions

Breastcancer; Perioperative Pain; Inflammation

Outcome Measures

Primary Outcomes (1)

• is to calculate total perioperative analgesia consumption throughout (24hours).

  24 hour postoperative

Study Arms (2)

will receive serratus posterior superior block using bupivacaine

ACTIVE COMPARATOR

between the SPSM and the 3rd rib after using a test dose of 1- 2 mL saline and Following hydro-dissection,30ml 0.25%bupivacaine will be injected.

Drug: Analgesia mangement group A,B

Arm B: (control group) patients will only receive general anesthesia without block.

OTHER

Narcotic postoperative

Drug: Analgesia mangement group A,B

Interventions

Analgesia mangement group A,B DRUG

1gm of paracetamol, 30mg of ketorolac and 1mg Granitryl will be given twenty minutes before the end of the operation .

Arm B: (control group) patients will only receive general anesthesia without block.; will receive serratus posterior superior block using bupivacaine

Eligibility Criteria

• Age: 21 Years - 60 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Adults undergoing unilateral breast surgery under general anesthesia
• Age 21 to 60 years with body mass index (BMI)=18 to 25 kg/m2
• American Society of Anesthesiologists (ASA) grade I-III.

You may not qualify if:

• Patients with Long-time use of analgesic drugs
• Past history of chest surgery,
• Allergy to local anesthetics,
• Systemic infection,
• Cognitive and language disorders precluding participation,
• Patients with coagulopathy,anticoagulant users
• hemodynamic unstable patients
• Patients with neurology, spinal, psychiatry diseases
• infection at block site
• patients refused to participate in the study .

Sponsors & Collaborators

• Ain Shams University: lead

MeSH Terms

Conditions

Inflammation

Condition Hierarchy (Ancestors)

Pathologic Processes; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Dalia Mostafa Ghazy, Master degree

CONTACT

01060192709; daliaibrahimghazy@med.asu.edu.eg

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 6, 2024
• First Posted: July 15, 2024
• Study Start: July 25, 2024
• Primary Completion: June 2, 2025
• Study Completion: July 1, 2025
• Last Updated: July 23, 2024

Record last verified: 2024-07